Lumos Diagnostics

#medtech #investing #diagnostics $LDX

Lumos is pleased to invite eligible shareholders to participate in our Share Purchase Plan (SPP) and Options Offer which opens today, with one free attaching option for every two SPP shares subscribed for. Please see Offer docs for details: lumosdiagnostics.com/spp

$LDX | @LumosDX announces new contract manufacturing agreement & first purchase order with Micro-Pak. Read the ASX release: bit.ly/3Ouev1j $LDX #Lumos #diagnostics #healthcare #manufacturing

$LDX #Lumos #FDA #diagnostics #healthcare #pointofcare #USExpansion

Lumos has announced that it has now received its largest purchase order to-date for FebriDx®, with its U.S. exclusive distribution partner PHASE Scientific placing an order valued at US$1.3 million. Read the ASX release: bit.ly/4uYZq8x

Investor webinar | Lumos will host a webinar on Tuesday 31 March at 9.00am (AEDT) to discuss the FDA CLIA waiver for FebriDx®, followed by a Q&A session. Register here: us02web.zoom.us/webinar/regist… $LDX #Lumos #FDA #rapidtest #FebriDx #pointofcare #diagnostics

Lumos has successfully completed a A$20.0 million institutional placement, with strong support from both existing and new investors, with proceeds to support the commercial rollout of FebriDX across the U.S. point-of-care market. Read the ASX announcement: bit.ly/3PqtYzM

$LDX #Lumos #FDA #rapidtest #FebriDx #pointofcare #diagnostics

Lumos Diagnostics has today announced that U.S. FDA has granted 510(k) clearance with CLIA waiver for FebriDx®, enabling broader use across frontline healthcare settings and unlocking a U.S. market opportunity of over US$1.0 billion. Read the ASX release: bit.ly/48d11h0

REPLAY | $LDX 1H FY26 Investor Briefing CEO Doug Ward and CFO Barrie Lambert discuss Lumos’ half-year performance, recent commercial and regulatory milestones, and the key priorities ahead as Lumos works toward CLIA waiver for FebriDx. Watch the replay: youtu.be/q2WnHtks4DI

$LDX #LDX #Lumos #rapidtext #pointofcare #healthcare #CLIAwaiver

Lumos has announced the completion of the first enrollment milestone in the ongoing BARDA-funded paediatric clinical study, triggering a milestone payment of US$720,000. Read the ASX announcement: bit.ly/3MKrbjF

Replay | This week $LDX CEO and MD, Doug Ward, and CFO, Barrie Lambert, presented the Company's Q2 FY26 quarterly results. The presentation includes an update on the FebriDx CLIA Waiver submission and key priorities for the next quarter. Take a look: bit.ly/49ZQEP5

The Armchair Analyst’s latest post, “Is the RAT Back? The Return of Rapid Point-of-Care Diagnostics”, explores renewed investor focus on rapid point-of-care diagnostics — with Lumos in the spotlight. Take a look: bit.ly/4kcCYU9 $LDX #LDX #Lumos #rapidtest #FebriDx

💻 Upcoming Webinar Lumos invites investors and analysts to attend webinar to discuss the Company’s the Q2 FY26 results. 📆 Tuesday, 3 February 2026 at 9:30am (AEDT). 🔗Participants can pre-register ahead of time via the following link: us02web.zoom.us/webinar/regist…

Lumos Diagnostics has released its Quarterly Activities Report for the period ending 31 December 2025. Read the ASX announcement: bit.ly/46en3z1 $LDX #Lumos #rapidtest #pointofcare #diagnostics #AMR #healthcare

REPLAY | Lumos Diganostics recently hosted a webinar exploring how Wellstreet Urgent Care has integrated FebriDx® into its outpatient workflows.  Take a look: bit.ly/3LDGpGF #LDX #pointofcare #diagnostics #healthcare

Lumos invites investors to a webinar this Friday 9 January on reducing diagnostic uncertainty in urgent care. Hear real-world insights on FebriDx® adoption at Wellstreet to support clinical decision-making.  Register for the webinar here: bit.ly/49p25hx  $LDX #Lumos

$LDX | Texas A&M University Health Services has adopted FebriDx® for routine use across its campus medical centers. Serving more than 80,000 students, the adoption supports point-of-care decision-making and helps reduce unnecessary antibiotic use.

Lumos Diagnostics has announced the execution of a new distribution agreement with the Interlux Group to commercialise FebriDx® across the Baltic region, covering Lithuania, Estonia and Latvia. Read the ASX announcement: bit.ly/3MPXkpK $LDX #LDX #Lumos #diagnostics